← AgentSite Network

triumvira.com

AI-friendly mirror of triumvira.com for archive, retrieval, and machine reading.

Total Pages
187
Total Words
73,242
Cache Generated
July 26, 2026
Resources
llms.txt— AI crawler index
sitemap.xml— XML sitemap
robots.txt— crawler directives
About this Cache— methodology and usage notes
Identity
primary.md— primary company profilepublic
identity.md— cache identity profilepublic
voice.md— voice and tone guidepublic
manifest.json— manifest metadatapublic
Content Index
▸website187 pages
Homepage
▸author14 pages
▸quik-2025x9 pages
Staff, Author at Triumvira Immunologics | Engineered T Cell Therapies - Page 9 of 9
Staff, Author at Triumvira Immunologics | Engineered T Cell Therapies - Page 8 of 9
Staff, Author at Triumvira Immunologics | Engineered T Cell Therapies - Page 7 of 9
Staff, Author at Triumvira Immunologics | Engineered T Cell Therapies - Page 6 of 9
Staff, Author at Triumvira Immunologics | Engineered T Cell Therapies - Page 5 of 9
… 4 more pages
▸triumvira15 pages
triumvira1, Author at Triumvira Immunologics | Engineered T Cell Therapies - Page 5 of 5
triumvira1, Author at Triumvira Immunologics | Engineered T Cell Therapies - Page 4 of 5
triumvira1, Author at Triumvira Immunologics | Engineered T Cell Therapies - Page 3 of 5
triumvira1, Author at Triumvira Immunologics | Engineered T Cell Therapies - Page 2 of 5
triumvira1, Author at Triumvira Immunologics | Engineered T Cell Therapies
view all 14 pages
▸category15 pages
Events Archives - Triumvira Immunologics | Engineered T Cell Therapies
▸press-releases7 pages
Press Releases & News Archives - Page 7 of 7 - Triumvira Immunologics | Engineered T Cell Therapies
Press Releases & News Archives - Page 6 of 7 - Triumvira Immunologics | Engineered T Cell Therapies
Press Releases & News Archives - Page 5 of 7 - Triumvira Immunologics | Engineered T Cell Therapies
Press Releases & News Archives - Page 4 of 7 - Triumvira Immunologics | Engineered T Cell Therapies
Press Releases & News Archives - Page 3 of 7 - Triumvira Immunologics | Engineered T Cell Therapies
… 2 more pages
▸publication3 pages
Publication Archives - Page 3 of 3 - Triumvira Immunologics | Engineered T Cell Therapies
Publication Archives - Page 2 of 3 - Triumvira Immunologics | Engineered T Cell Therapies
Publication Archives - Triumvira Immunologics | Engineered T Cell Therapies
▸news-articles4 pages
News Articles Archives - Page 4 of 4 - Triumvira Immunologics | Engineered T Cell Therapies
News Articles Archives - Page 3 of 4 - Triumvira Immunologics | Engineered T Cell Therapies
News Articles Archives - Page 2 of 4 - Triumvira Immunologics | Engineered T Cell Therapies
News Articles Archives - Triumvira Immunologics | Engineered T Cell Therapies
view all 15 pages
▸wp-content16 pages
▸uploads16 pages
SITC Poster 2022 - GUCY2C v7.cdr
SITC 2023 Clinical Poster.cdr
ESMO Poster 2022 Draft 10.cdr
SITC Poster 2022 Clinical Poster.cdr
SITC Poster 2022 - MoA_CWH.cdr
… 11 more pages
view all 16 pages
Page not found - Triumvira Immunologics | Engineered T Cell Therapies
▸programs2 pages
Page not found - Triumvira Immunologics | Engineered T Cell Therapies
TAC101-CLDN18.2 - Triumvira Immunologics | Engineered T Cell Therapies
view all 2 pages
Page not found - Triumvira Immunologics | Engineered T Cell Therapies
patient-derived-tac01-her2-tac-t-cells-produced-in-cocoon-platform-is-highly-functional-in-models-of-solid-tumors
a-phase-i-ii-trial-investigating-safety-and-efficacy-of-autologous-tac01-her2-in-relapsed-or-refractory-solid-tumors
Privacy Policy - Triumvira Immunologics | Engineered T Cell Therapies
biotech-cfos-sharpen-financing-tactics-for-lean-times
Page not found - Triumvira Immunologics | Engineered T Cell Therapies
Terms of Use - Triumvira Immunologics | Engineered T Cell Therapies
T Cell Therapy - Triumvira Immunologics | Engineered T Cell Therapies
designed-ankyrin-repeat-proteins-are-effective-targeting-elements-for-chimeric-antigen-receptors
▸about-us2 pages
Company Overview - Triumvira Immunologics | Engineered T Cell Therapies
Contact - Triumvira Immunologics | Engineered T Cell Therapies
view all 2 pages
▸affilation3 pages
Management Archives - Triumvira Immunologics | Engineered T Cell Therapies
Scientific Advisory Council Archives - Triumvira Immunologics | Engineered T Cell Therapies
Board of Directors Archives - Triumvira Immunologics | Engineered T Cell Therapies
view all 3 pages
▸our-technology2 pages
How It Works - Triumvira Immunologics | Engineered T Cell Therapies
Our Technology - Triumvira Immunologics | Engineered T Cell Therapies
view all 2 pages
▸job3 pages
Job Title - Triumvira Immunologics | Engineered T Cell Therapies
Job Title - Triumvira Immunologics | Engineered T Cell Therapies
Job Title - Triumvira Immunologics | Engineered T Cell Therapies
view all 3 pages
Presentations & Publications - Triumvira Immunologics | Engineered T Cell Therapies
News Articles - Triumvira Immunologics | Engineered T Cell Therapies
A Phase 1/2 Study Evaluating the Safety and Efficacy of Autologous TAC-T Cells in Subjects with Claudin 18.2+ Advanced Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Presents Updated Clinical Data at the 2025 ASCO Gastrointestinal Cancers Symposium - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics' Late-Breaking Abstract Selected for Oral Presentation at the 39th SITC Annual Meeting Demonstrates Preliminary Safety and Promising Clinical Activity of TAC01-CLDN18.2 Cell Therapy in Patients with Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies
A Phase 1/2 Study Evaluating the Safety and Efficacy of Autologous TAC-T Cells in Subjects with Claudin 18.2+ Advanced Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics to Present New Clinical Data from Ongoing Claudin 18.2 Phase 1 Study in Late-Breaking Oral Presentation at 39th SITC Annual Meeting - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Announces Publication Demonstrating the Safety and Efficacy of TAC T Cells Targeting Claudin 18.2 in Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Pivots to Claudin 18.2-Targeted Cell Therapy, Pauses HER2 Program - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Announces First Patient Dosed in Phase I/II Cell Therapy Trial of TAC101-CLDN18.2 for the Treatment of Claudin 18.2+ Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies
JPM2024: On the Ground in San Francisco - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Takes A Different TAC With T-Cell Therapy For Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies
FDA’s CAR T Probe ‘Not a Big Deal’ for Oncology-Focused Biotechs: Triumvira President - Triumvira Immunologics | Engineered T Cell Therapies
Alternative Funding Strategies to Discuss at JPM - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics to Present Clinical Data at the 2024 ASCO Gastrointestinal Cancers Symposium - Triumvira Immunologics | Engineered T Cell Therapies
What Do You See As The Most Significant Regulatory Decision Or Guidance On The Horizon For 2024 (Or Beyond)? - Triumvira Immunologics | Engineered T Cell Therapies
Six biopharma executives consider a tough 2023 and are hopeful for a better 2024 - Triumvira Immunologics | Engineered T Cell Therapies
Immune Cell Therapy May Become More Naturalistic - Triumvira Immunologics | Engineered T Cell Therapies
Finance And Funding: Anticipating Improvement, Planning For Uncertainty - Triumvira Immunologics | Engineered T Cell Therapies
Preclinical Characterization and Modeling of Allogeneic Vγ9Vδ2 TAC T Cells for the Treatment of Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies
TAC-T Cells Persist and Remain Functional During and After Repeated Tumor Exposure In Vitor and In Vivo - Triumvira Immunologics | Engineered T Cell Therapies
A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects with Unresectable, Locally Advanced or Metastatic CLDN18.2+ Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies
A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC01-HER2 in Relapsed or Refractory Solid Tumors (TACTIC-2) - Triumvira Immunologics | Engineered T Cell Therapies
Development of GUCY2C-TAC T Cells for the Treatment of Colorectal Cancer - Triumvira Immunologics | Engineered T Cell Therapies
First Patient Dosed in Study of Cell Therapy for Gastric Cancer - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics to Present New Clinical and Preclinical Data on its TAC-T Cell Technology at SITC 2023 Annual Meeting - Triumvira Immunologics | Engineered T Cell Therapies
Phase 2 of TACTIC-2 Begins Dosing TAC01-HER2 in HER2+ Gastric/GEJ Cancer - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Begins Phase II Trial of T-Cell Therapy in HER2-Positive Gastric Cancer - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Announces First Patient Dosed in Phase II of TACTIC-2 Cell Therapy Trial for the Treatment of HER2+ Gastric and GEJ Cancers - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics to Present Clinical Data from TACTIC-2 Trial Investigating TAC01-HER2 at ESMO 2023 Congress and AACR-NCI-EORTC International Conference - Triumvira Immunologics | Engineered T Cell Therapies
The Top 25 Healthcare Technology Leaders of Austin for 2023 - Triumvira Immunologics | Engineered T Cell Therapies
Decoding Cell Therapy Variants with Dr Andy Bader - Triumvira Immunologics | Engineered T Cell Therapies
Conquering New Frontiers in Cell Therapy, Paul Lammers, CEO, Triumvira Immunologics - Triumvira Immunologics | Engineered T Cell Therapies
Advancements in Cell Therapy for Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies
Biotech M&A Rebound Bodes Well for Venture Investors - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Strengthens its Leadership Team with Three Accomplished Life Sciences Executives - Triumvira Immunologics | Engineered T Cell Therapies
Claudin-18.2 attracts the cancer crowd - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics to Showcase Clinical Findings from TACTIC-2 Clinical Trial Assessing TAC01-HER2 at 2023 ESMO World Congress on Gastrointestinal Cancer - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira shares upcoming plans for accelerated approval with cell therapies - Triumvira Immunologics | Engineered T Cell Therapies
DDW Events: AACR 2023 Episode 2 with Andreas Bader, Triumvira Immunologics - Triumvira Immunologics | Engineered T Cell Therapies
Dr Schlechter on TAC01-HER2 Therapy in HER2+ Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Highlights Positive Phase 1 Clinical Data on TAC01-HER2 in Solid Tumors at ASCO 2023 Annual Meeting - Triumvira Immunologics | Engineered T Cell Therapies
A Different Approach, A New Cancer Drug... Dr. Paul Lammers, CEO Triumvira Immunologics - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics to Present Clinical Data from Phase I/II Trial TACTIC-2 Investigating TAC01-HER2 at the 2023 ASCO Annual Meeting - Triumvira Immunologics | Engineered T Cell Therapies
Joy and Boldness in Drug Development – with Paul Lammers - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Presents Promising Data on TAC T Cells for the Treatment of HER2-overexpressing Solid Tumors at the 2023 AACR Annual Meeting - Triumvira Immunologics | Engineered T Cell Therapies
Engineering Better Cell Therapies for Cancers - Triumvira Immunologics | Engineered T Cell Therapies
First in Human Episode #25 featuring Dr. Paul Lammers - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics - T-Cell Therapeutics - Triumvira Immunologics | Engineered T Cell Therapies
On the Backside of the Hype Cycle: Cancer Cell Therapy Companies Grappling with Lofty Expectations and Challenging Market Conditions - Triumvira Immunologics | Engineered T Cell Therapies
JPM Highlights: What’s Next in ImmunoOncology - Triumvira Immunologics | Engineered T Cell Therapies
SVB fall casts shadow on early-stage U.S. biotech - Triumvira Immunologics | Engineered T Cell Therapies
T Cell Antigen Coupler Platform Generating Patient-Derived Cell Therapies to Target Solid Tumors with Dr. Paul Lammers Triumvira Immunologics - Triumvira Immunologics | Engineered T Cell Therapies
Inside Insight: Nature knows best for Triumvira's cell therapy - Triumvira Immunologics | Engineered T Cell Therapies
Biotech CFOs sharpen financing tactics for lean times - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Establishes Collaboration with Merck to Evaluate TAC01-HER2 Cell Therapy in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2-positive Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies
Other news to note for Jan. 5, 2023 - Triumvira Immunologics | Engineered T Cell Therapies
Tales From the 2022 Biotech VC Fundraising Trail - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Announces Updated Data from Ongoing TACTIC‑2 Trial of TAC01-HER2 in Patients with HER2 Positive Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies
A Phase I/II Trial Investigation Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refactory Solid Tumors (Tactic-2) - Triumvira Immunologics | Engineered T Cell Therapies
Evidence for Durable Anti-Tumor Responses by TAC-T Cells in Preclinical Models of Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies
Development of GUCY2C-TAC T Cells for the Treatment of Colorectal Cancer - Triumvira Immunologics | Engineered T Cell Therapies
Preclinical Studies of TAC01-CLDN18.2, an Autologous Claudin 18.2-Directed TACT T Cell Therapy, for the Treatment of Gastric Cancer - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Demonstrates Strength of Preclinical Research Pipeline for Gastric and Colorectal Cancers in Three Posters at SITC 2022 - Triumvira Immunologics | Engineered T Cell Therapies
Benjamin L. Schlechter, MD, on Addressing Unmet Needs in HER2 Positive Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics to Present Clinical and Preclinical Updates at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Appoints Life Sciences Industry Leader Robert Williamson as President and Chief Business Officer - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Announces Expansion of Cell Therapy Manufacturing Capabilities to Facility in South San Francisco - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics to Participate in Four Upcoming Healthcare Investor Conferences in October and November 2022 - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Presents Initial HER2-Positive Solid Tumor Clinical Data at ESMO - Triumvira Immunologics | Engineered T Cell Therapies
A Phase I/II Trial Investigating Safety and Efficacy of Autologous T Cell Antigen-Coupler (TAC) T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors (TACTIC-2) (ESMO Report) - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics to Present Interim Clinical Data from Ongoing Phase 1/2 Trial with T Cell Therapy TAC01-HER2 at European Society for Medical Oncology 2022 Congress - Triumvira Immunologics | Engineered T Cell Therapies
A Phase I/II Trial Investigating Safety and Efficacy of Autologous T Cell Antigen-Coupler (TAC) T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors (TACTIC-2) - Triumvira Immunologics | Engineered T Cell Therapies
CAR T cells headline HER2 cell therapy pipeline - Triumvira Immunologics | Engineered T Cell Therapies
L7 Informatics and Triumvira Immunologics Announce Agreement to Digitalize Manufacturing of Next-Generation Cell Therapies - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics to Present Two Posters Covering Ongoing Phase 1/2 Solid Tumor Trial and New Preclinical Gastric Cancer Data at AACR Annual Meeting 2022 - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Completes Extension of Series A Financing, for Total Round of Approximately $100 Million - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Establishes Scientific Advisory Board - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Announces Data from Gastric Cancer Preclinical Study to be Presented at SITC Annual Meeting - Triumvira Immunologics | Engineered T Cell Therapies
Development of Claudin 18.2-TAC T Cells for the Treatment of Gastric Cancer - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Appoints Oncology Industry Veteran Deyaa Adib, M.D., as Chief Medical Officer - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Doses First Patient with Novel T Cell Therapy in TACTIC-2 Clinical Trial - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Appoints Teresa McRoberts as Chief Financial Officer and Announces Senior Level Promotions - Triumvira Immunologics | Engineered T Cell Therapies
Top Life Sciences Startups to Watch in 2021 - Triumvira Immunologics | Engineered T Cell Therapies
Bayer and Northpond Ventures Lead USD $55 Million Series A Financing Round for Triumvira Immunologics - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Announces Grant of T Cell Antigen Coupler (TAC) Technology Patent by U.S. Patent and Trademark Office - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics and Lonza Announce Collaboration to Develop Innovative Point-of-Care Manufacturing for TAC T-Cell Therapeutic Targeting Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Announces Fast Track Designation for Its First TAC T-Cell Therapeutic Product Candidate: TAC01-CD19 - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Announces Clearance of IND and CTA by U.S. FDA and Health Canada for Its First TAC T-cell Therapeutic Product Candidate, TAC01-CD19 - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Announces Addition of Veteran VP of Regulatory Affairs, Presentations at CellCAN and TRI-CON Conferences, and Attendance at Bio-Europe Partnering - Triumvira Immunologics | Engineered T Cell Therapies
Q&A with Dr. Paul Lammers, President and CEO of Triumvira Immunologics developing their T-Cell Antigen Coupler Technology to activate T-Cells in the treatment of Advanced Hematological Cancers and Solid Tumors - Triumvira Immunologics | Engineered T Cell Therapies
Knight Therapeutics and Triumvira Immunologics Triumphantly Announce Secured Bridge Loan & License Agreement - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics to Present at CAR-T Congress EU in London, UK - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Announces Build Out of Senior Management Team with Addition of Industry-Experienced Professionals in R&D and Business Development - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics to Present at Biotech Showcase™ 2019 in San Francisco - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Demonstrates Prolonged TAC-T Cell Persistence and Efficacy in Preclinical Models - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Announces Presentation of Key Preclinical Data on TAC Technology at American Society of Hematology - Triumvira Immunologics | Engineered T Cell Therapies
CCAB And Triumvira Immunologics Announce Triumvira’s License Agreement with University of Toronto for the Discovery of Antibody Drug Development Candidates - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Presents Data on T Cell Antigen Coupler (TAC) Technology at the 6th Annual Immuno-Oncology Summit - Triumvira Immunologics | Engineered T Cell Therapies
The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity - Triumvira Immunologics | Engineered T Cell Therapies
Nature Communications Publishes Studies Comparing Triumvira’s T Cell Antigen Coupler (TAC) Technology with CAR T Cell Therapy - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Appoints Scott Smith to Board of Directors - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Hires Donna Rill as Chief Technology Officer - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics to Participate in Two Upcoming Conferences - Triumvira Immunologics | Engineered T Cell Therapies
4th Annual Immuno-Oncology BD&L and Investment Forum - Triumvira Immunologics | Engineered T Cell Therapies
2018 BIO International Convention - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Expands Management Team with Chief Medical Officer and VP, Finance - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Announces Strategic Relationship for GMP Manufacturing with Centre for Commercialisation of Cancer Immunotherapy - Triumvira Immunologics | Engineered T Cell Therapies
International Society for Cellular Therapy 2018 - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics to Present at Two Upcoming Conferences: - Triumvira Immunologics | Engineered T Cell Therapies
Bloom Burton & Co. Healthcare Investor Conference - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Appoints Cynthia Collins to Board of Directors - Triumvira Immunologics | Engineered T Cell Therapies
LaVoieHealthScience Expands Senior Leadership Team, Adds Two New Immuno-Oncology Clients to Roster - Triumvira Immunologics | Engineered T Cell Therapies
Paul Lammers, M.D., M.Sc. Joins Triumvira as President and Chief Executive Officer - Triumvira Immunologics | Engineered T Cell Therapies
Hamilton researchers: White blood cells could be made to hunt cancer cells - Triumvira Immunologics | Engineered T Cell Therapies
Tumor-targeting domains for chimeric antigen receptor T cells - Triumvira Immunologics | Engineered T Cell Therapies
Viral Engineering of Chimeric Antigen Receptor Expression on Murine and Human T Lymphocytes - Triumvira Immunologics | Engineered T Cell Therapies
Chimeric antigen receptor-engineered T cells as oncolytic virus carriers - Triumvira Immunologics | Engineered T Cell Therapies
T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice - Triumvira Immunologics | Engineered T Cell Therapies